Inflammation and vascular dysfunction

B. Staels (Lille, France)

Source: Research Seminar 2007 - Metabolic Aspects of the Obstructive Sleep Apnea Syndrome (OSAS)
Number: 9
Disease area: Sleep and breathing disorders

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Staels (Lille, France). Inflammation and vascular dysfunction. Research Seminar 2007 - Metabolic Aspects of the Obstructive Sleep Apnea Syndrome (OSAS)

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Impaired endothelial vasoreactivity and markers of systemic inflammation in overlap syndrome
Source: Annual Congress 2013 –Sleep disordered breathing in special situations I
Year: 2013

Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021
Year: 2021

Vascular dysfunction and systemic inflammation in patients with COPD
Source: Annual Congress 2011 - COPD: human studies
Year: 2011

Systemic inflammation and vascular dysfunction in patients with OSA
Source: Annual Congress 2011 - Obstructive sleep apnoea: clinical aspects I
Year: 2011

Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012

Systemic inflammation and endothelial dysfunction in patient with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007

Endothelial dysfunction of patients with pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 25s
Year: 2002

Endothelial dysfunction as systemic effects of COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 652s
Year: 2006

Primary pulmonary hypertension and endothelial dysfunction
Source: Eur Respir J 2003; 22: Suppl. 45, 583s
Year: 2003

Endothelial and platelet dysfunction in pulmonary hypertension due to sarcoidosis
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008

Correction of endothelial dysfunction in patients with pulmonary diseases
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008

Pulmonary vascular cell mitochondrial dysfunction in response to hepcidin
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019

Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction
Source: Eur Respir J 2006; 28: Suppl. 50, 548s
Year: 2006

Role of endothelin-1 in endothelial dysfunction in cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007

Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013

The evaluation of airways mucosa vascular endothelial dysfunction
Source: Eur Respir J 2004; 24: Suppl. 48, 560s
Year: 2004

Endothelial dysfunction and arterial rigidity in patients with bronchial asthma out of an exacerbation
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013

Cardiac dysfunction
Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC
Year: 2021